Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04408261
Other study ID # 2017L04609
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date July 22, 2020
Est. completion date December 2022

Study information

Verified date May 2020
Source Dongzhimen Hospital, Beijing
Contact Ying Gao, MD
Phone 0086-010-84013209
Email gaoying973@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this trial is to evaluate the efficacy and safety of Buqitongluo Granule in treating qi deficiency and blood stasis syndrome, and explore the effect of the improvement of qi deficiency and blood stasis syndrome on the prognosis of diseases.


Description:

The BOSS study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The primary hypothesis of this trial is that Buqitongluo Granule will improve the syndrome score of Qi Deficiency and Blood Stasis in convalescence of ischemic stroke, stable angina pectoris of coronary artery disease and diabetic peripheral neuropathy with qi deficiency and blood stasis syndrome. Buqitongluo Granule will be compared to placebo, combined with guidelines-based standard care in patients. During the trial, it is forbidden to use acupuncture, Traditional Chinese Medicine decoction (compound granule), Traditional Chinese Medicine injection, Chinese patent medicine (including external use), external washing of Traditional Chinese Medicine and health product (composition or efficacy similar to the study drug).


Recruitment information / eligibility

Status Recruiting
Enrollment 432
Est. completion date December 2022
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender All
Age group 35 Years to 80 Years
Eligibility Convalescence of ischemic stroke Inclusion Criteria: - Diagnosis of qi deficiency and blood stasis syndrome - Diagnosis of ischemic stroke - Age = 35 and = 80 years - The interval from the onset to recruitment was 14-30 days - NIHSS score = 4 and = 22 - Patient or legally authorized representative has signed informed consent. Exclusion Criteria: - Confirmed secondary stroke caused by tumor, brain trauma, or hematological diseases by clinical examination; - Other conditions that lead to motor dysfunction (e.g. lameness, osteoarthrosis, rheumatoid arthritis, gouty arthritis), which render the neurological function examination unlikely to be assessed; - Uncontrolled hypertension (systolic blood pressure = 160 mmHg or diastolic blood pressure = 100 mmHg), or renal or hepatic insufficiency (hepatic insufficiency is defined as an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value that is 1.5 times the upper limit of normal, renal insufficiency is defined as a serum creatinine concentration value that is over the upper limit of normal); - Other conditions or mental disorders which according to the judgement of researchers that restrict evaluation of mental function or render outcomes or follow-up unlikely to be assessed; - Woman with pregnancy, lactation, or woman who wants to be pregnant in recent; - Patient who is allergic to the study drug or has severe allergic constitution; - Patient with yellow thick slimy tongue coating; - Patient who has been participated in other drug or device clinical trials in recent 3 months. Stable angina pectoris of coronary artery disease Inclusion Criteria: - Diagnosis of qi deficiency and blood stasis syndrome - Diagnosis of stable angina pectoris of coronary artery disease - Age = 35 and = 80 years - Canadian Cardiovascular Society (CCS) Classification of Angina Pectoris class?-? - Patient or legally authorized representative has signed informed consent. Exclusion Criteria: - Acute coronary syndrome or unstable angina pectoris in the prior 3 months, or other heart diseases (e.g. cardiomyopathy, pericardial disease); - Severe cardiopulmonary insufficiency (congestive heart failure NYHA class IV, severe abnormal pulmonary function), or severe arrhythmias (e.g. rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia); - Uncontrolled hypertension (systolic blood pressure = 160 mmHg or diastolic blood pressure = 100 mmHg), or renal or hepatic insufficiency (hepatic insufficiency is defined as an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value that is 1.5 times the upper limit of normal, renal insufficiency is defined as a serum creatinine concentration value that is over the upper limit of normal); - Other conditions or mental disorders which according to the judgement of researchers that restrict evaluation of mental function or render outcomes or follow-up unlikely to be assessed; - Woman with pregnancy, lactation, or woman who wants to be pregnant in recent; - Patient who is allergic to the study drug or has severe allergic constitution; - Patient with yellow thick slimy tongue coating; - Patient who has been participated in other drug or device clinical trials in recent 3 months. Diabetic peripheral neuropathy Inclusion Criteria: - Diagnosis of qi deficiency and blood stasis syndrome - Diagnosis of diabetic peripheral neuropathies - Age = 35 and = 80 years - Patient or legally authorized representative has signed informed consent. Exclusion Criteria: - HbA1c >10% in the screening period; - Acute critical disease of diabetes mellitus in the prior 3 months (e.g. hyperglycemia and hypertonic syndrome, diabetic lactic acidosis, diabetic ketoacidosis); - Severe heart disease, brain disease, or kidney disease; - Uncontrolled hypertension (systolic blood pressure = 160 mmHg or diastolic blood pressure = 100 mmHg), or renal or hepatic insufficiency (hepatic insufficiency is defined as an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value that is 1.5 times the upper limit of normal, renal insufficiency is defined as a serum creatinine concentration value that is over the upper limit of normal); - Patient with spinal cord injury, cervical or lumbar vertebra disease (nerve root compression, spinal stenosis, cervical or lumbar vertebra degenerative disease), or sequelae of cerebrovascular disease, neuromuscular junction or muscular disease; - Neuropathies caused by other diseases (e.g. Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), VitB deficiency, hypothyroidism, alcoholism, severe arteriovenous vasculopathy such as venous embolism, lymphangitis); - Other conditions or mental disorders which according to the judgement of researchers that restrict evaluation of mental function or render outcomes or follow-up unlikely to be assessed; - Woman with pregnancy, lactation, or woman who wants to be pregnant in recent; - Patient who is allergic to the study drug or has severe allergic constitution; - Patient with yellow thick slimy tongue coating; - Patient with red tongue and scanty tongue coating; - Patient who has been participated in other drug or device clinical trials in recent 3 months.

Study Design


Intervention

Drug:
Buqitongluo Granule
Buqitongluo Granules were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
Buqitongluo Granule Placebo
Buqitongluo Granule placeboes were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
Other:
Standard care
Guidelines-based standard care for convalescence of ischemic stroke, stable angina pectoris of coronary artery disease or diabetic peripheral neuropathy.

Locations

Country Name City State
China Dongzhimen Hospital Beijing Beijing

Sponsors (18)

Lead Sponsor Collaborator
Dongzhimen Hospital, Beijing Beijing Chuanglikechuang Medical Technology Development Co., Ltd., Hunan Academy of Traditional Chinese Medicine Affiliated Hospital, Jiangbin Hospital of Guangxi Zhuang Autonomous Region, Rizhao Hospital of Traditional Chinese Medicine, Shaanxi Buchang Pharmaceuticals Co., Ltd., Shanghai Youningwei Biotechnology Co., Ltd., The Affiliated Hospital of Changchun University of Chinese Medicine, The Affiliated Hospital of Chengdu University of Chinese Medicine, The Affiliated Hospital of Shandong University of Chinese Medicine, The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine, The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, The First Clinical Hospital of Jilin Academy of Traditional Chinese Medicine, The Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, The Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine, The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Wuhan Third Hospital-Tongren Hospital of Wuhan University, Wuhan Zhizhi Medical Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the syndrome score of Qi Deficiency and Blood Stasis The dynamic evaluation will be defined by Evaluation Scale of Qi Deficiency and Blood Stasis Syndrome. The Evaluation Scale of Qi Deficiency and Blood Stasis Syndrome score ranges from 0 (best score) to 51 (worst score). Baseline, at day 14, day 28, day 42 during treatment, and at day 14 after treatment
Secondary Neurological impairment will be evaluated by National Institute of Health Stroke Scale (NIHSS) for convalescence of ischemic stroke The NIHSS score ranges from 0 (best score) to 42 (worst score). Baseline, at day 14, day 28, day 42 during treatment
Secondary Self-rating symptoms will be evaluated by Visual Analog Scale (VAS) for convalescence of ischemic stroke Including limb numbness, swelling of hands or feet, spontaneous sweating (hemilateral sweating). Participants rated their symptoms on the 100 millimeter (mm) Visual Analog Scale (VAS) ranging from 0 mm (no symptom) to 100 mm (worst symptom). Baseline, at day 14, day 28, day 42 during treatment, and at day 14 after treatment
Secondary Continuous changes of Modified Rankin Scale for convalescence of ischemic stroke The Modified Rankin Scale score ranges from 0 (best score) to 6 (worst score). Baseline, at day 42 during treatment, and at 90 days after onset
Secondary Activities of daily living will be measured by Barthel Index (BI) score for convalescence of ischemic stroke The Barthel Index score ranges from 0 (worst score) to 100 (best score). Baseline, at day 42 during treatment, and at 90 days after onset
Secondary Quality of life will be measured by Short Form 36 (SF-36) Quality of Life Scale for convalescence of ischemic stroke The SF-36 quality of life scale is used to monitor change in subject reported functionality, well-being, and overall health status. The score of each part ranges from 0 (worst score) to 100 (best score). Baseline, at day 42 during treatment, and at 90 days after onset
Secondary Change of the Seattle Angina Questionnaire (SAQ) Score for stable angina pectoris of coronary artery disease The maximum score is 100, and the higher the score, the better the quality of life and the state of body function of patient. Baseline, at day 28 during treatment, at day 14 after treatment, and at 90 days after recruitment
Secondary Self-rating symptoms will be evaluated by Visual Analog Scale (VAS) for stable angina pectoris of coronary artery disease Including chest tightness, chest pain, palpitation, fatigue, spontaneous sweating. Participants rated their symptoms on the 100 millimeter (mm) Visual Analog Scale (VAS) ranging from 0 mm (no symptom) to 100 mm (worst symptom). Baseline, at day 14, day 28, day 42 during treatment, and at day 14 after treatment
Secondary Change of the Clinical Scoring System of Toronto (TCSS) for diabetic peripheral neuropathy TCSS includes a score of neural symptoms, nerve reflex scores and sensory examination. The TCSS score ranges from 0 (best score) to 19 (worst score). Baseline, at day 14, day 28, day 42 during treatment, at day 14 after treatment, and at 90 days after recruitment
Secondary Self-rating symptoms will be evaluated by Visual Analog Scale (VAS) for diabetic peripheral neuropathy Including local pain, limb numbness, paresthesia (e.g. burning sensation, formication, electrical sensation). Participants rated their symptoms on the 100 millimeter (mm) Visual Analog Scale (VAS) ranging from 0 mm (no symptom) to 100 mm (worst symptom). Baseline, at day 14, day 28, day 42 during treatment, and at day 14 after treatment
Secondary Quality of life will be measured by Short Form 36 (SF-36) Quality of Life Scale for stable angina pectoris of coronary artery disease and diabetic peripheral neuropathy The SF-36 quality of life scale is used to monitor change in subject reported functionality, well-being, and overall health status. The score of each part ranges from 0 (worst score) to 100 (best score). Baseline, at day 42 during treatment, and at 90 days after recruitment
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A